Assertio Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq retreat from record highs as yields and oil climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
Assertio Therapeutics (ASRT) Misses Q2 EPS by 32c, Revenues Miss
August 7, 2020 6:19 AM EDTAssertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of ($0.35), $0.32 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $20.62 million versus the consensus estimate of $25.33 million.
Even in what has been an unprecedented time with patient volume and elective... More



